Dr Reddy's inks new deal with Gland Pharma in the US market

Indian drug major Dr Reddy’s Laboratories (BSE: 500124) has entered into a strategic collaboration with Gland Pharma, a developer and manufacturer of sterile dosage forms, to market and distribute a diverse portfolio of eight injectable Abbreviated New Drug Applications (ANDAs).

The portfolio is a mix of filed ANDAs pending approval by the US Food and Drug Administration and ANDAs that will be filed imminently, and comprised of generic injectables administered in hospitals and clinics in the USA. The combined sale of branded and generic versions of the products in the USA is about $ 1 billion for the most recent 12 months ending in August 2016, according to IMS Health data quoted by Dr Reddy’s.

Alok Sonig, executive vice president and head of North America for Dr Reddy’s, said: “We are excited about this opportunity. Dr Reddy’s Laboratories has a strong track record in developing, marketing and distributing generic injectables in the US. Our strengths, combined with Gland’s track record of manufacturing and operational excellence, will help bring affordable medications within reach of patients and complement our specialty injectables offering in the short-to-medium term.”